-
公开(公告)号：US12071415B2
公开(公告)日：2024-08-27
申请号：US17233171
申请日：2021-04-16
IPC分类号： C07D291/06 , C07C69/757 , C07C311/19 , C07D207/36 , C07D231/20 , C07D239/62 , C07D275/04 , C07D285/01 , C07D307/60 , C07D333/32 , C07D401/06 , C07D403/06 , C07D409/06 , C07D417/06
CPC分类号： C07D291/06 , C07C69/757 , C07C311/19 , C07D207/36 , C07D231/20 , C07D239/62 , C07D275/04 , C07D285/01 , C07D307/60 , C07D333/32 , C07D401/06 , C07D403/06 , C07D409/06 , C07D417/06
摘要： The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.
-
公开(公告)号：US20230234944A1
公开(公告)日：2023-07-27
申请号：US18008871
申请日：2021-06-07
申请人： TOYAMA PREFECTURAL UNIVERSITY , TEIKA PHARMACEUTICAL CO., LTD. , NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
IPC分类号： C07D405/10 , C07C219/30 , C07D307/94 , C07D295/185 , C07C219/22 , C07D211/38 , C07D295/096 , C07D205/04 , C07C43/178 , C07C43/23 , C07C33/38 , C07C57/48 , C07C69/757 , C07C311/04 , A61P37/06
CPC分类号： C07D405/10 , C07C219/30 , C07D307/94 , C07D295/185 , C07C219/22 , C07D211/38 , C07D295/096 , C07D205/04 , C07C43/1788 , C07C43/23 , C07C33/38 , C07C57/48 , C07C69/757 , C07C311/04 , A61P37/06
摘要： CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.
-
公开(公告)号：US11130726B2
公开(公告)日：2021-09-28
申请号：US16685335
申请日：2019-11-15
IPC分类号： C07C62/38 , C07C62/34 , C07C229/48 , C07D211/22 , C07C317/44 , C07C323/61 , C07C69/757 , A61P25/00 , A61P29/00 , A61P17/04 , C07C313/04
摘要： The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
-
公开(公告)号：US11098267B2
公开(公告)日：2021-08-24
申请号：US16881513
申请日：2020-05-22
发明人： Mitsuharu Kitamura
IPC分类号： C11B9/00 , A61K8/37 , A23L2/56 , A23L27/20 , A61Q13/00 , C11D3/50 , C07C69/753 , C07C69/757 , A61K47/14
摘要： A perfume composition containing a compound represented by the following formula (1): wherein R1, R2 and R3 are independently hydrogen or a methyl group, X is an alkyl group having 1 to 4 carbon atoms, R4 and R5 are independently hydrogen or a —CHO group, and AA is a single bond or a double bond, has an excellent aroma and aroma persistence useful as a compound perfume material.
-
公开(公告)号：US20210238155A1
公开(公告)日：2021-08-05
申请号：US17233171
申请日：2021-04-16
发明人： Binghe Wang , Xingyue Ji , Ladie Kim De La Cruz , Xiaoxiao Yang
IPC分类号： C07D291/06 , C07C69/757 , C07D307/60 , C07D275/04 , C07D285/01 , C07D207/36 , C07D333/32 , C07D231/20 , C07D239/62 , C07D417/06 , C07D401/06 , C07D403/06 , C07C311/19 , C07D409/06
摘要： The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.
-
公开(公告)号：US10995051B2
公开(公告)日：2021-05-04
申请号：US16731705
申请日：2019-12-31
申请人： L'OREAL
发明人： Maria Dalko , Xavier Marat , Julien Hitce , Chao-Jun Li
IPC分类号： C07C45/69 , C07C59/11 , C07C51/38 , C07C69/675 , C07C45/54 , C07C67/347 , C07C69/757 , C07C69/732 , C07C69/734 , C07D213/30 , A61K8/365 , A61Q17/00 , A61Q19/00 , C07C51/09 , C07C59/54 , C07C59/56 , C07C59/72
摘要： The present invention relates to compounds of formula (I): in which R1 is a hydrogen atom, a phenyl radical, or a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms.
-
公开(公告)号：US20210122700A1
公开(公告)日：2021-04-29
申请号：US16965343
申请日：2019-02-01
发明人： Anders Bue Klein , Andrew Neil Clarkson , Joshua Macdonald Houlton , Ulrike Leurs , Rasmus Prætorius Clausen , Bente Frølund , Petrine Wellendorph
IPC分类号： C07C69/757 , C07C59/56 , C07C59/54 , C07C69/732 , A61P25/00
摘要： The invention relates to a compound according to formula I wherein when R5 is H, and R1 and R2 form a ring system, then said compound is selected from the following compounds of formula II or formula IV or when R2 is H, and R1 and R5 form a ring system, then said compound has formula III
-
公开(公告)号：US10959989B2
公开(公告)日：2021-03-30
申请号：US16866995
申请日：2020-05-05
发明人： Peter Qinhua Huang , Deborah Helen Slee , Sayee Gajanan Hegde , Chad Daniel Hopkins , Kevin Duane Bunker , Joseph Robert Pinchman , Rakesh Kumar Sit
IPC分类号： C07D209/10 , A61K31/438 , C07C69/738 , C07C69/732 , C07D471/04 , C07B59/00 , C07C69/757 , A61P5/30 , A61P35/00 , A61K31/437
摘要： Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
-
公开(公告)号：US10941095B2
公开(公告)日：2021-03-09
申请号：US16142547
申请日：2018-09-26
IPC分类号： C07C31/27 , C07C61/12 , C07C47/34 , C07C309/25 , C07F9/24 , C07D261/12 , C07C59/105 , C07C33/26 , C07C47/19 , C07C69/675 , C07C69/003 , C07C69/017 , C07C309/08 , C07F9/11 , C07C309/24 , C07F9/12 , C07D495/04 , C07C255/00 , C07D257/04 , C07D261/08 , C07D305/12 , C07D307/33 , C07C59/01 , C07D309/30 , A61K31/194 , A61K31/23 , A61K31/20 , A61K31/191 , C07C31/20 , C07C31/22 , C07C31/24 , C07C59/11 , C07C59/285 , C07C59/29 , C07C59/46 , C07C59/48 , C07C59/54 , C07C62/06 , C07C65/17 , C07C69/757 , C07D213/80 , C07D309/10 , C07D309/12 , C07D405/12 , C07F9/09 , C07F9/117 , C07F9/44 , C07C59/245 , C07C62/02
摘要： The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
-
公开(公告)号：US20210040028A1
公开(公告)日：2021-02-11
申请号：US17077133
申请日：2020-10-22
申请人： SYMRISE AG
发明人： Michael Backes , Jakob Peter Ley , Andreas Degenhardt , Susanne Paetz , Katharina Reichelt , Thomas Riess , Bettina Klose , Fabia Hentschel
IPC分类号： C07C69/734 , A23L27/20 , A23L27/00 , A61K47/14 , C07C69/708 , C07C69/757 , A23B4/06
摘要： Compounds of formula (I) and novel uses of compounds of formula (I), such as for flavour compositions. New preparations and new methods using compounds of formula (I).
-
-
-
-
-
-
-
-
-
搜索结果
620 条记录 (耗时 0.027 秒)
